NRTI, NNRTI, PI and cocktail treatment have two unconquered disadvantages: drug resistance and high toxicity. Whereas, fusion inhibitors, whose target is gp41 protein, have advantages, such as lower toxicity, less drug resistance, inhibiting HIV at the early stage and action outside cells. Therefore, they will improve life quality of HIV/AIDS patients. Sifuvirtide belongs to the new type of anti-HIV drugs—fusion inhibitor.

Sifuvirtide belongs to peptide drugs, whose administration route is subcutaneous injection. Results of HIV infected persons in phase Ib and IIa clinical trials indicated: 20 mg Sifuvirtide daily had a significant efficacy for early HIV infected persons. Thereby, the frequency of Sifuvirtide injection is temporally intended to be 20 mg once daily, which was lower than that of other fusion inhibitors (B.I.D) and some traditional anti-HIV drugs (B.I.D or T.I.D). This not only makes anti-HIV/AIDS treatment easier, but is conducive to raise patients’ compliance and to reduce influence on patients’ daily life as well.

It seems to be not difficult. After patients accept a simple training, it is not difficult for them to administrate Sifuvirtide independently (just as the independent SC injection of insulin for diabetic patients)

Sifuvirtide is still in Phase II clinical trial now. After the whole clinical trials are completed, results will be submitted to SFDA. If SFDA authorized Sifuvirtide, the drug will just be marketed. If you want to get this drug now, you could enter our clinical trials.

Our company will carry out Sifuvirtide phase IIb clinical trial in spring, 2007, and we are recruiting volunteers form the public now. If you want to enter our clinical trials, you can fill in the registration forms online (http://www.fusogen.com/clinical-trial.asp). We will guarantee your privacy. You can consult us if you have any questions. Our telephone number is 86-22-83865829, and transfer Clinical Trial Consulting. (9:00 - 17:00 from Monday to Friday).

According to related state regulations, patients with CD4 < 200 cells/mm3 or 200 ~ 350 cells/mm3 (reduction > 30% within one year) need to initiate antiviral treatment. Based on your information, we think you need not to initiate antiviral treatment now, but need to see your doctor and do related examinations on time.

It may be caused by HIV drug resistance. We suggest you take HIV-1 resistance genotyping test in related hospital, and changed drugs in “cocktail treatment” according to doctor's advice.